查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924682

吸入式SEVOFLURANE麻醉剂市场按产品类型、应用、最终用户和分销管道划分－2026-2032年全球预测

Inhalation Sevoflurane Anesthesia Drugs Market by Product Type, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，吸入式SEVOFLURANE麻醉剂市场价值将达到 12.8 亿美元，到 2026 年将成长至 13.9 亿美元，到 2032 年将达到 24.3 亿美元，复合年增长率为 9.62%。

关键市场统计数据
基准年 2025 12.8亿美元
预计年份：2026年 13.9亿美元
预测年份 2032 24.3亿美元
复合年增长率 (%) 9.62%

本文简要概述了现代SEVOFLURANE麻醉领域的临床意义、供应趋势和策略影响。

吸入麻醉剂SEVOFLURANE因其优异的药物动力学特性、可预测的起效和恢復特性以及与多种给药系统的兼容性，仍然是现代麻醉实践中的核心药物。本执行摘要了近期影响SEVOFLURANE的临床趋势、供应链发展、产品创新和监管动态。它阐述了临床需求、技术变革和政策转变如何共同影响医院、门诊机构和其他医疗机构的筹资策略。

製剂、法律规范、通路和临床应用方面的重大模式转移正在重塑SEVOFLURANE的供应和采购格局。

过去几年，受製剂技术、给药方式和临床需求的创新驱动，SEVOFLURANE市场格局发生了翻天覆地的变化。随着麻醉场所从传统手术室扩展到门诊手术中心和家庭麻醉支持，麻醉剂的分销模式也从散装液体转向更便捷的即用型产品，促使生产商投资研发与现代麻醉给药系统兼容的预填充式注射器和蒸发器药筒。

美国新关税调整对SEVOFLURANE市场的影响，包括筹资策略重组、供应商选择和供应链弹性规划。

2025年，美国提高关税的实施为依赖进口的SEVOFLURANE供应链环节带来了额外的成本考量，促使采购和生产策略做出显着调整。进口商和经销商试图透过重新评估定价结构、重新谈判供应合约以及加快与国内生产商的咨询来降低关税波动带来的风险。因此，医院和门诊中心的采购部门越来越倾向于选择具备本地生产能力和透明落地成本模式的供应商。

综合細項分析揭示了临床应用、最终用户概况、产品形式和分销管道如何共同定义了SEVOFLURANE的需求概况。

要了解SEVOFLURANE市场，需要深入理解临床应用、终端用户、产品类型和分销管道如何相互作用，从而影响其供需特征。在应用方面，七氟烷的应用场景多种多样，包括门诊麻醉；全身麻醉（又细分为心臟手术、住院手术和神经外科手术）；儿童麻醉（分为日间护理和住院两种）；以及兽医用途，每种用途都有其独特的操作、剂量和采购要求。在终端使用者方面，SEVOFLURANE供应给门诊手术中心、诊所、居家医疗机构和医院，这些机构又可进一步细分为政府机构和私人机构，它们在采购政策、预算週期和法律规范存在差异。

从区域观点审视美洲、欧洲、中东和非洲以及亚太地区的监管差异、临床应用模式和供应链设计至关重要。

区域趋势对SEVOFLURANE的临床应用、监管路径和供应链结构具有决定性影响。在美洲，成熟的医院系统和广泛的门诊网络推动了对散装和即用型七氟烷的稳定需求，而成熟的采购流程和大规模集团采购组织的存在则影响着谈判能力和供应连续性策略。在欧洲、中东和非洲地区，不同的法规环境和国内生产能力的不均衡分配，需要采取差异化的分销方式。有些市场倾向于集中竞标，而有些市场则由区域分销商来弥补物流和合规方面的不足。

製造卓越性、经销伙伴和产品供应创新等策略竞争因素正在重新定义企业在SEVOFLURANE市场的定位。

SEVOFLURANE市场的竞争格局主要取决于製造商的大规模生产能力、配方技术、品管系统和分销管道。投资于经过检验的无菌生产线、完善的品质保证流程和多样化的包装方案的公司，更有能力满足医院药房和门诊医疗机构的需求。此外，与分销网络和医院系统建立策略合作伙伴关係，可以提高产品知名度，并推动即用型製剂的普及。投资与蒸发器相容的药筒和预填充给药系统正成为差异化优势，尤其是在手术室吞吐量和污染控制至关重要的环境中。

为製造商、医疗服务提供者和采购主管提供切实可行的策略建议，以优化供应链弹性、临床应用和商业性成果。

产业领导者应采取多管齐下的策略，兼顾临床偏好、供应弹性以及不断变化的采购模式。首先，应优先投资于即用型给药系统，例如预填充式注射器和与蒸发器相容的药筒，以满足门诊护理和高通量手术环境的需求，因为在这些环境中，速度和无菌性至关重要。其次，应实现製造地和采购管道的多元化，以减少对单一供应商的依赖，并降低关税和地缘政治风险。第三，应加强与医院药局的合作，提供以结果为导向的服务模式，包括产品操作训练、一次性使用方案和库存优化通讯协定。

为了确保研究结果的可靠性和可操作性，我们采用了严格的混合方法研究设计，结合了主要临床访谈、有针对性的次要研究和检验通讯协定。

本执行摘要的研究采用了混合方法，结合了初步访谈、有针对性的二手资料研究和交叉检验，以确保研究结果的可靠性。一级资讯来源包括与临床麻醉医师、医院药房主任、门诊和住院采购人员以及供应链经理的结构化访谈，旨在深入了解药物储存、配製和给药方面的实际挑战。二手资料分析则纳入了监管指南、生产最佳实践和已发表的临床文献，以阐明实际操作情况和产品设计考量。

将临床连续性和商业性转型结合，凸显了产品设计、製造韧性和分销灵活性的内在一致性。

对SEVOFLURANE市场的全面分析凸显了其在商业性和营运方面发生的显着变化，以及稳定的临床需求。临床医生仍然重视SEVOFLURANE可预测的药理特性，儘管通路和产品形式有所变化，但这种临床偏好仍然支撑着其采购优先顺序。同时，从关税带来的成本压力到对即用型给药系统日益增长的需求，各种商业性因素正在重塑医疗机构采购和使用这种麻醉剂的方式。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 吸入式SEVOFLURANE麻醉剂市场（依产品类型划分）

  • 散装液体
  • 即用型

9. 吸入式SEVOFLURANE麻醉剂市场依应用领域划分

  • 门诊麻醉
  • 全身麻醉
    • 心臟手术
    • 医院手术
    • 神经外科
  • 儿童麻醉
    • 日托
    • 住院病人
  • 兽医护理

10. 吸入式SEVOFLURANE麻醉剂市场（依最终用户划分）

  • 门诊手术中心
  • 诊所
  • 居家医疗机构
  • 医院
    • 公立医院
    • 私立医院

11. 吸入式SEVOFLURANE麻醉剂市场依分销管道划分

  • 离线
  • 在线的

12. 各地区吸入式SEVOFLURANE麻醉剂市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 吸入式SEVOFLURANE麻醉剂市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国吸入式七SEVOFLURANE麻醉剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国吸入式SEVOFLURANE麻醉剂市场

第十六章：中国吸入式七SEVOFLURANE麻醉剂市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Anhil Parenterals Pvt. Ltd.
  • AstraZeneca plc
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Fresenius Kabi AG
  • Gujarat Medicraft Private Limited
  • Halocarbon Life Sciences, LLC
  • Hikma Pharmaceuticals PLC
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Lunan Pharmaceutical Group Co., Ltd.
  • Maruishi Pharmaceutical Co., Ltd.
  • Mylan NV
  • Neon Laboratories Ltd.
  • Novartis AG
  • Piramal Enterprises Ltd.
  • Questus Pharma Pvt. Ltd.
  • Shanghai Hengrui Pharmaceutical Co., Ltd.
  • Troikaa Pharmaceuticals Ltd.
Product Code: MRR-7A380DA7C420

The Inhalation Sevoflurane Anesthesia Drugs Market was valued at USD 1.28 billion in 2025 and is projected to grow to USD 1.39 billion in 2026, with a CAGR of 9.62%, reaching USD 2.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.28 billion
Estimated Year [2026] USD 1.39 billion
Forecast Year [2032] USD 2.43 billion
CAGR (%) 9.62%

Concise overview of the clinical relevance, supply dynamics, and strategic implications defining the contemporary sevoflurane anesthesia environment

The inhalational anesthetic sevoflurane remains a core agent in contemporary anesthesia practice due to its favorable pharmacokinetic profile, predictable onset and recovery characteristics, and compatibility with a wide range of delivery systems. This executive summary synthesizes recent clinical trends, supply chain dynamics, product innovations, and regulatory developments shaping the sevoflurane landscape. It contextualizes how clinical demand, technology shifts, and policy changes are converging to influence procurement strategies in hospitals, outpatient facilities, and alternative care settings.

Across care environments, clinicians continue to prioritize agents that offer rapid titratability, hemodynamic stability, and efficient recovery, and sevoflurane often meets these clinical desiderata. At the same time, manufacturers and providers are adapting to evolving expectations for ready-to-use formats and optimized supply chains. This summary outlines the most consequential inflection points and offers a clear vantage for stakeholders to align operational, clinical, and commercial planning. By underscoring strategic levers and practical implications, the content prepares clinical leaders, procurement teams, and product strategists to respond effectively to immediate challenges and emerging opportunities.

Significant paradigm shifts in formulation, regulatory oversight, distribution channels, and clinical use that are reshaping sevoflurane delivery and procurement

Over the past several years, the sevoflurane landscape has experienced transformative shifts driven by innovations in formulation, delivery formats, and clinical expectations. Transitioning from bulk liquid distribution to more convenient ready-to-use formats has accelerated as care settings broaden beyond the traditional operating room into ambulatory surgical centers and home-based anesthesia support, prompting manufacturers to invest in prefilled syringes and vaporizer cartridges compatible with modern anesthesia delivery systems.

Concurrently, regulatory focus on sterility assurance and labeling clarity has prompted revisions to manufacturing controls and packaging standards, encouraging more stringent quality oversight. This regulatory tightening has gone hand in hand with supply chain reconfiguration: companies are diversifying manufacturing footprints and reinforcing cold-chain and controlled-handling processes to reduce single-source vulnerabilities. Clinically, the push toward enhanced recovery protocols and shorter turnover times has increased demand for agents that facilitate rapid emergence, benefiting sevoflurane's clinical positioning. Finally, distribution strategies are evolving; hospital pharmacies, direct tenders, and e-pharmacy platforms are each reshaping how sevoflurane is procured and stocked, which in turn affects pricing negotiation, inventory management, and contingency planning for high-volume institutions.

How newly implemented United States tariff adjustments have restructured procurement tactics, supplier preferences, and supply chain resilience planning in the sevoflurane market

In 2025 the imposition of increased tariffs in the United States introduced an additional layer of cost consideration for import-dependent segments of the sevoflurane supply chain, prompting visible adjustments across procurement and manufacturing strategies. Importers and distributors responded by reassessing price structures, renegotiating supply agreements, and accelerating discussions with domestic manufacturers to mitigate exposure to tariff volatility. Consequently, procurement teams at hospitals and ambulatory centers began to place a higher premium on suppliers with local or regional manufacturing capabilities and transparent landed cost models.

Tariffs have also catalyzed strategic hedging behaviors among manufacturers, leading some to reconfigure supply routes and inventory staging practices. In parallel, service providers and group purchasing organizations sharpened contractual clauses to distribute tariff risk more equitably among stakeholders. Clinicians and pharmacy directors have observed shifts in supplier diversity, with an increasing preference for vendors capable of guaranteeing supply continuity under variable tariff regimes. While these measures do not alter clinical guidelines for sevoflurane use, they do shape the commercial calculus for institutions balancing cost containment with the imperative to maintain uninterrupted access to clinically preferred anesthetic agents.

Integrated segmentation insights revealing how clinical applications, end-user profiles, product formats, and distribution channels collectively define sevoflurane demand characteristics

Understanding the sevoflurane market requires a nuanced view of how clinical applications, end users, product types, and distribution channels interact to shape demand and supply characteristics. By application, use cases span ambulatory anesthesia, general anesthesia with subdivisions for cardiac surgery, inpatient surgery, and neurosurgery, pediatric anesthesia segmented into day care and inpatient contexts, and veterinary applications, each presenting distinct handling, dosing, and procurement requirements. By end user, sevoflurane serves ambulatory surgical centers, clinics, home care settings, and hospitals, with hospitals further differentiated between government and private institutions that exhibit divergent purchasing policies, budget cycles, and regulatory oversight.

Product type segmentation differentiates bulk liquid presentations and ready-to-use formats. Bulk liquid typically arrives in 250 ml or 500 ml bottles intended for centralized pharmacy compounding and vaporizer filling, whereas ready-to-use options include prefilled syringes and vaporizer cartridges designed to reduce preparation time and contamination risk. Distribution channels encompass direct tender processes, hospital pharmacy procurement, online pharmacy platforms, and retail pharmacy points of sale, with retail further split across chain and independent pharmacies that vary in procurement scale and service level agreements. These intersecting dimensions influence inventory norms, cold-chain and sterility controls, clinician preferences, and the economics of conversion from bulk to ready-to-use solutions, thereby guiding product development and commercial positioning.

Compelling regional perspectives on regulatory nuance, clinical adoption patterns, and supply chain design across Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a decisive influence on clinical adoption, regulatory pathways, and supply chain architecture for sevoflurane. In the Americas, mature hospital systems and extensive ambulatory networks drive steady demand for both bulk and ready-to-use formats, while procurement sophistication and the presence of large group purchasing organizations shape negotiation leverage and supply continuity strategies. In Europe, Middle East & Africa, heterogeneous regulatory environments and variable access to domestic manufacturing capacity necessitate differentiated distribution approaches, with some markets favoring centralized tenders and others relying on regional distributors to bridge logistics and compliance gaps.

Across the Asia-Pacific region, rapid expansion of surgical infrastructure, growing volumes of day-case procedures, and increasing attention to perioperative efficiency are accelerating uptake of ready-to-use delivery formats and vaporizer-compatible cartridges. Each region presents unique regulatory, logistical, and clinical practice nuances that affect lead times, packaging preferences, and vendor selection. Stakeholders must therefore adapt commercial models to the regulatory cadence and procurement culture of each geography, aligning supply chain investments with regional demand patterns and the evolving clinical emphasis on fast recovery and operational throughput.

Strategic competitive factors including manufacturing excellence, distribution partnerships, and product delivery innovation that are redefining players' positioning in the sevoflurane arena

Competitive dynamics in the sevoflurane space are shaped by manufacturers' capabilities in scale manufacturing, formulation expertise, quality systems, and distribution reach. Firms that invest in validated sterile production lines, robust quality assurance processes, and versatile packaging options are better positioned to meet the dual demands of hospital pharmacies and ambulatory providers. Moreover, strategic partnerships with distribution networks and hospital systems enhance product visibility and facilitate adoption of ready-to-use formats. Investment in vaporizer-compatible cartridges and prefilled delivery systems is becoming a differentiator, particularly where operating room throughput and contamination control are prioritized.

Beyond manufacturing capabilities, companies that proactively engage with regulatory authorities and clinical stakeholders to support post-market surveillance and education initiatives build trust and reduce friction in uptake. In addition, entities focused on supply chain transparency-providing clear traceability, batch-level documentation, and responsive logistics-tend to secure longer-term contracts with large institutional buyers. Private equity activity and M&A among mid-sized suppliers are also reshaping the competitive map, as consolidation enables scaling of sterile manufacturing assets and broader geographic distribution networks. Ultimately, success depends on aligning product innovation with operational realities of end users and the evolving expectations of procurement stakeholders.

Actionable strategic recommendations for manufacturers, healthcare providers, and procurement leaders to optimize supply resilience, clinical adoption, and commercial outcomes

Industry leaders should adopt a multi-pronged strategy that addresses clinical preferences, supply resilience, and evolving procurement models. First, prioritize investments in ready-to-use delivery systems such as prefilled syringes and vaporizer-compatible cartridges to accommodate ambulatory and high-throughput surgical settings where speed and sterility matter most. Second, diversify manufacturing and sourcing footprints to reduce reliance on single-source suppliers and to mitigate tariff exposure and geopolitical risk. Third, strengthen hospital pharmacy collaborations by offering outcome-oriented service models that include education on product handling, single-use options, and inventory optimization protocols.

In parallel, companies and health systems should enhance traceability and transparency across the supply chain, delivering batch-level documentation and predictable lead times to procurement teams. Engagement with regulatory bodies should be proactive, focusing on demonstrating robust sterility controls and post-market surveillance to preempt compliance challenges. Finally, consider subscription-style or value-based contracting arrangements that align supplier incentives with institutional goals for availability, cost predictability, and patient throughput. Taken together, these measures create a resilient, clinically attuned approach that balances operational efficiency with the imperative of uninterrupted access to preferred anesthetic agents.

Rigorous mixed-methods research design integrating primary clinical interviews, targeted secondary review, and triangulation protocols to ensure reliable and actionable insights

The research underpinning this executive summary employed a mixed-methods approach combining primary interviews, targeted secondary research, and cross-validation to ensure robust findings. Primary inputs included structured discussions with clinical anesthesiologists, hospital pharmacy directors, procurement leaders from ambulatory and inpatient settings, and supply chain managers, enabling direct insight into practical challenges of storage, preparation, and administration. Secondary analysis incorporated regulatory guidance, manufacturing best practices, and public domain clinical literature to contextualize operational realities and product design considerations.

Data triangulation was used to reconcile divergent stakeholder perspectives and to surface consistent themes such as the preference for ready-to-use formats in high-throughput environments and heightened concern for supply continuity under tariff-driven cost pressures. Quality controls included source verification, timestamped interview logs, and a sensitivity review with external clinical advisors to ensure clinical assertions were aligned with accepted practice. Wherever quantitative datasets were referenced, methodological caveats were applied to preserve clarity regarding data provenance and to avoid extrapolation beyond validated evidence. This methodological rigor supports actionable, defensible conclusions that stakeholders can use to inform procurement, product development, and operational planning.

Synthesis of clinical continuity and commercial transformation highlighting the essential alignment of product design, manufacturing resilience, and distribution agility

The cumulative picture of the sevoflurane landscape emphasizes stability in clinical demand alongside notable commercial and operational evolution. Clinicians continue to value sevoflurane for its predictable pharmacologic characteristics, and this clinical preference anchors procurement priorities even as distribution channels and product formats shift. Simultaneously, commercial forces-ranging from tariff-driven cost pressures to a growing appetite for ready-to-use delivery systems-are reshaping the ways in which institutions source and administer this anesthetic.

For healthcare leaders and manufacturers alike, the imperative is to align product design, manufacturing resilience, and distribution agility with the clinical workflow realities of modern perioperative care. By doing so, stakeholders can sustain clinical excellence while reducing exposure to supply disruption and cost volatility. The conclusion underscores a clear imperative: integrate clinical input into commercial strategy, invest in diversified and validated manufacturing, and pursue distribution models that reflect the operational priorities of end users to secure reliable access to sevoflurane across care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Inhalation Sevoflurane Anesthesia Drugs Market, by Product Type

  • 8.1. Bulk Liquid
  • 8.2. Ready To Use

9. Inhalation Sevoflurane Anesthesia Drugs Market, by Application

  • 9.1. Ambulatory Anesthesia
  • 9.2. General Anesthesia
    • 9.2.1. Cardiac Surgery
    • 9.2.2. Inpatient Surgery
    • 9.2.3. Neurosurgery
  • 9.3. Pediatric Anesthesia
    • 9.3.1. Day Care
    • 9.3.2. Inpatient
  • 9.4. Veterinary

10. Inhalation Sevoflurane Anesthesia Drugs Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Clinics
  • 10.3. Home Care Settings
  • 10.4. Hospitals
    • 10.4.1. Government Hospitals
    • 10.4.2. Private Hospitals

11. Inhalation Sevoflurane Anesthesia Drugs Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Inhalation Sevoflurane Anesthesia Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Inhalation Sevoflurane Anesthesia Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Inhalation Sevoflurane Anesthesia Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Inhalation Sevoflurane Anesthesia Drugs Market

16. China Inhalation Sevoflurane Anesthesia Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AbbVie Inc.
  • 17.7. Anhil Parenterals Pvt. Ltd.
  • 17.8. AstraZeneca plc
  • 17.9. B. Braun Melsungen AG
  • 17.10. Baxter International Inc.
  • 17.11. Fresenius Kabi AG
  • 17.12. Gujarat Medicraft Private Limited
  • 17.13. Halocarbon Life Sciences, LLC
  • 17.14. Hikma Pharmaceuticals PLC
  • 17.15. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 17.16. Lunan Pharmaceutical Group Co., Ltd.
  • 17.17. Maruishi Pharmaceutical Co., Ltd.
  • 17.18. Mylan N.V.
  • 17.19. Neon Laboratories Ltd.
  • 17.20. Novartis AG
  • 17.21. Piramal Enterprises Ltd.
  • 17.22. Questus Pharma Pvt. Ltd.
  • 17.23. Shanghai Hengrui Pharmaceutical Co., Ltd.
  • 17.24. Troikaa Pharmaceuticals Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY BULK LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY BULK LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY BULK LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY READY TO USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY READY TO USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY READY TO USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY AMBULATORY ANESTHESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY AMBULATORY ANESTHESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY AMBULATORY ANESTHESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY CARDIAC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY CARDIAC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY CARDIAC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY INPATIENT SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY INPATIENT SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY INPATIENT SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY NEUROSURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY NEUROSURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY NEUROSURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DAY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DAY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DAY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY VETERINARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY VETERINARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY VETERINARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. GCC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 144. GCC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 145. GCC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 147. GCC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. G7 INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 168. G7 INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 169. G7 INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. G7 INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. NATO INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 176. NATO INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 177. NATO INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 179. NATO INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)